Misha Roshal is a practicing hematopathologist, associate attending physician, and director of the clinical flow cytometry laboratory in the department of pathology in Memorial Sloan Kettering Cancer Center. His major clinical expertise is in development of robust flow cytometry-based assays for assessment of treatment response of hematologic neoplasms. His laboratory has developed assays for high sensitivity measurable residual disease in acute myeloid and lymphoid leukemias, myeloma, and CLL. In addition, they have acquired an expertise in evaluation of hematologic response to novel therapeutic agents in phase I/II clinical trials including evaluation of drug-induced maturation state changes via cell surface biomarker assessment. His major research interests are in molecular genetic characterization of treatment resistant and rare disease populations and in defining molecular genetic triggers of lineage infidelity and unusual differentiation pathways in acute leukemia. These studies have led to identification of specific mutations associated with lineage infidelity and plasmacytoid dendritic cell maturation as well as mutation combinations and phenotypes associated with decreased MRD clearance in AML.